The National Agency for Food and Drug Administration and Control (NAFDAC) says it approved the emergency use of AstraZeneca vaccine (EUL) also known as Covishield, manufactured under license by Serum Institute of India.
The NAFDAC Director-General, Prof. Mojisola Adeyeye, said this on Thursday at a press briefing in Abuja.
Adeyeye said the recommendation for Emergency Use Authorization was based on rigorous scientific considerations.
She said: “NAFDAC is the first National Regulatory Agency in Africa to have Guidance on Regulatory Preparedness for EUA, Licensing or Access to COVID-19 Vaccines.
“The agency established the COVID-19 Vaccine Committee and has been busy developing guidelines and guidance.
“The NAFDAC received the AstraZeneca/Oxford COVID-19 vaccine dossier from Serum Institute of India on February 10, 2021.
“The NAFDAC Vaccine Committee commenced the expedited review immediately and the members of the committee have worked assiduously to ensure that review was done as planned. The recommendation for Emergency Use Authorization was based on rigorous scientific considerations.”
